Company Presentation

Pitch & Match

Through Pitch & Match, we provide our investors and presenting companies the opportunity to know each other before event day, get engaged through presentation, Q&A and arrange immediate follow-up meetings.

Presentation fees: $3000 (Includes presentation fee and one registration for presenter)

Presentation Companies Can:

  • Meet pre-vetted decision makers from top Chinese pharma and investment firms
  • Know your audience prior to the pitch
  • Maximized your company visibility through pre-conference promotion
  • Present for 8min with Powerpoint
  • Schedule immediate follow-up meetings through on-target partnering

Who Should Apply

•    Biotech

•    Drug development

•    Platform technology

•    Medical device

•    Digital health

Opportunities our audience are seeking

•    Equity Investment

•    Licensing

•    Co-Development

•    M&A

•    Joint Venture

•    And more…

Featured Audiences

Hengrui Pharmaceuticals

Description: A leading biopharmaceutical company based in China with annual sales of $2.2 billion in 2017 and a market cap of $31 billion.

Recent Deal: Mycovia and Hengrui Medicine have signed an agreement to develop and commercialise the former’s investigational drug, VT-1161 for RVVC

Interests: oncology, autoimmune, metabolic and CV

CSPC

Description: CSPC was recognized as the top brand for its compliance culture, ethical business and innovation

Recent Deal: Verastem grants CSPC exclusive rights to develop and commercialize the cancer drug Copiktra duvelisib in China.

Interests: Oncology, CV, Autoimmune

 

Fosun Pharma

Description: Established innovative chemical drugs platform, biologics platform, high-value generic drugs platform and cell-therapy platform.

Recent Deal: Revance Therapeutics grants Fosun exclusive Chinese rights to RT002.

Interests: oncology, cardiovascular disease, CNS, liver disease, medical device

Salubris Pharmaceuticals

Description: Salubris is a globally integrated pharmaceutical group dedicated to the research, development, manufacture, marketing, distribution.

Recent Deal: Viracta Therapeutics Inc. granted Salubris exclusive rights to develop and sell its virus-related cancer therapy nanatinostat/valganciclovir in the great China.

Interests: Oncology, CV and metabolic diseases

Luye Pharma

Description: Luye Pharma is an international pharmaceutical company with a robust pipeline of 40 drug candidates in China and more than 10 drug candidates overseas.

Recent Deal: Luye Pharma and PharmaMar Sign Licensing Agreement for the Development and Commercialization of Zepsyre® in China.

Interests: Oncology, CNS, CV, diabetes, digestive disease and metabolic diseases

Huadong Medicine

Description: A fully integrated pharmaceutical company focused on discovery, development, manufacturing and commercialization of medicines, with annual revenue of 4.5 billion USD.

Recent Deal: Huadong Medicine Co Ltd. Gains Access to Sinclair Pharma’s Highly Differentiated Aesthetics Products to Expand Business Beyond China into United States and Other Markets

Interests: Diabetes, Aesthetics, autoimmune disease, digestive disease, CV, oncology, and infectious disease.

More featured audience to be announced